Mutation Analysis of the Iduronate-2-Sulfatase Gene among Egyptian Patients with Hunter Syndrome | ||
| Middle East Journal of Medical Genetics | ||
| Volume 13, Issue 2, July 2024, Pages 1-9 PDF (479.79 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mxe.2025.362459.1036 | ||
| Authors | ||
| Nouran Mohamed Sedky* 1; Mona Salem Khalil2; Nahed Mohamed Ibrahim2; Ekram Mahamed Fateen3; Mona Mohamed Ibrahim4; Mona Sabry Aglan5; Heba Amin Hassan6; Mona Lotfi Essawi6 | ||
| 1Medical Molecular Genetics, National Research Centre, Cairo, Egypt | ||
| 2Clinical and Chemical Chemistry, Faculty of medicine, Ksr Eleny Cairo University, Cairo, Egypt | ||
| 3Biochemical Genetics, Division of Human Genetics and Genome Research, National Research Centre, Cairo, Egypt | ||
| 4Biochemical Genetics, Division of Human Genetics and Genome Research, National Research Centre, Dokki12311, Cairo, Egypt | ||
| 5Clinical Genetics, Division of Human Genetics and Genome Research, National Research Centre, Cairo, Egypt | ||
| 6Medical Molecular Genetics, Division of Human Genetics and Genome Research, National Research Centre, Cairo, Egypt | ||
| Abstract | ||
| Background: Mucopolysaccharidosis type II (Hunter syndrome) an X-linked disorder mostly due to mutations in the gene responsible for production of the enzyme iduronate-2-sulfatase (IDS). It belongs to subgroup of diseases called mucopolysaccharidoses caused by accumulation of lysosomal material. It is a rare disease worldwide, having an incidence of 0.3–0.7 per 100,000 live births. Its primary cause is due to mutation affecting the IDS gene causing in accordance deficiency in the lysosomal enzyme activity. The IDS enzyme catalyzes the catabolism of glycosaminoglycans (GAGs), resulting in the accumulation of dermatan and heparan sulphates in different body tissues mainly in connective tissue, spleen, liver, and brain, with elimination of large amounts of them in the urine. The clinical spectrum can be divided into mild, intermediate, and severe variants. The patients clinically are characterized by coarsening of their facial structures, joint and bone deformities, short stature, changes in different body systems including cardiac, respiratory, ocular and olfactory systems and in severe cases troubled motor function, advanced learning complications and behavioral abnormalities can occur. To date, 792 variants have been reported by the HGMD associated with MPS type II have been identified. The study was conducted on fifteen Egyptian male patients from unrelated families with Hunter syndrome to study the molecular basis of Hunter disease among Egyptian patients through determination of iduronate 2- sulfatase gene mutations. Patients had hepatosplenomegaly, ENT problems mostly due to enlarged adenoids, central nervous system (CNS) abnormality and delayed IQ. Five novel and four previously reported mutations were detected in nine of our patients. Our study being the first Egyptian study on Hunter syndrome has shown as other studies that most mutations of MPS II appear to be unique and there is a great variety between the different populations in the presentation of the disease with different mutations | ||
| Keywords | ||
| Glycosaminoglycans; hunter syndrome; IDS gene; lysosomal; mucopolysaccharidosis | ||
|
Statistics Article View: 65 |
||
